Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656142 | 0.89 | LMNA (0.53) | CAMK2DCNR2CNR1PRPS1DYRK1A | |
| SCHEMBL6073315 | 0.87 | CAMK2D (0.42) | CAMK2DCNR2CNR1DYRK1A | |
| SCHEMBL6073784 | 0.86 | CAMK2D (0.42) | CAMK2DCNR2CNR1DYRK1A | |
| SCHEMBL29324307 | 0.79 | LMNA (0.53) | CAMK2DCNR2 | |
| SCHEMBL15798230 | 0.79 | DYRK1A (0.56) | CAMK2DCNR2DYRK1A | |
| SCHEMBL9319939 | 0.79 | ALDH1A1 (0.42) | CAMK2D | |
| SCHEMBL4176799 | 0.76 | ALDH1A1 (0.43) | CAMK2DCNR2 | |
| SCHEMBL4653711 | 0.76 | P2RX3 (0.41) | CAMK2DCNR2CNR1DYRK1A | |
| SCHEMBL4654813 | 0.75 | KMT2A (0.44) | CAMK2DCNR2CNR1DYRK1A | |
| SCHEMBL25381100 | 0.75 | CAMK2D (0.48) | CAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-6743412-B2 | ADMINISTERING TO TREAT RHEUMATOID ARTHRITIS, CANCER, RESTENOSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6689337-B2 | TARGETING MOIETY OF A QUINOLONE NONPEPTIDE BOUND TO A CHELATOR AND ALSO BINDS TO A RECEPTOR THAT IS UPREGULATED DURING ANGIOGENESIS; IMAGING COMPOUNDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-6683163-B2 | MONITORING ANGIOGENESIS FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-01-27 | — | — | US | disclosed |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | HARRIS THOMAS D (US) | 2003-07-03 | — | — | US | disclosed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6524553-B2 | A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a qinolone nonpeptide, and binds to a receptor that is upregulated during angiogenesis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6511649-B1 | Chemotherapeutic, a radiosensitizer agent, and a targeting moiety bound to chelator and is a quinolone nonpeptide that binds to a receptor; therapeutically effective radioisotope or diagnostically effective imageable moiety; cancer | LANTHEUS MI REAL ESTATE, LLC | 2003-01-28 | — | — | US | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | CITIZENS BANK, N.A. | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124120-A1 | Quinolone vitronectin receptor antagonist pharmaceuticals | ADGRF1, QRFPR, ADGRE5 | CAMK2D 1759/4885CNR2 78/4885CNR1 52/4885 |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | CAMK2D 2093/4885CNR2 662/4885CNR1 610/4885 |
| US-20020015680-A1 | QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, QRFPR, ADGRE5 | CAMK2D 1759/4885CNR2 78/4885CNR1 52/4885 |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CAMK2D 1194/4885CNR2 106/4885CNR1 85/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CAMK2D 1359/4885CNR2 106/4885CNR1 77/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | CAMK2D 1194/4885CNR2 106/4885CNR1 85/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | CAMK2D 1194/4885CNR2 106/4885CNR1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.